BioStem Technologies, Inc., was incorporated in Utah on July 7, 2006 and re-registered in Florida on March 2, 2009. BioStem Technologies, Inc., is a regenerative medicine company focused on the development and commercialization of perinatal tissue-based therapies for advanced wound care and surgery. The company utilizes proprietary processing technology to give full play to the natural characteristics of perinatal tissue, providing solutions designed to support tissue repair and regeneration. Its product portfolio primarily includes placenta-derived allografts, covering both dry and cryopreservation options, which act as a protective barrier to support the body's own healing process in a variety of clinical settings. The Company's technology is designed to address diseases such as diabetic foot ulcers, venous leg ulcers, pressure ulcers, traumatic wounds and surgical incisions to facilitate faster healing and reduce overall treatment costs. The clinical benefits of these techniques have been evaluated in prospective controlled clinical trials and retrospective data analysis, showing that these techniques improve patient outcomes compared to standard treatment. The Company has expanded its product portfolio through strategic acquisitions and plans to continue to develop complementary regenerative therapies to meet unmet needs in wound management and surgical healing.
